

Supplementary Appendix of

**Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of SARS-CoV-2 infection in the general population: a head-to-head comparison**

Ewoud Schuit, Roderick P Venekamp, Irene K Veldhuijzen, Wouter van den Bijllaardt, Suzan D Pas, Joep J J M Stohr, Esther B Lodder, Marloes Hellwich, Richard Molenkamp, Zsofia Igloi, Constantijn Wijers, Irene H Vroom, Carla R S Nagel-Imming, Wanda G H Han, Jan AJW Kluytmans, Susan van den Hof, Janneke H H M van de Wijgert, Karel G M Moons

Table of contents

<b>Supplementary material 1: short questionnaire after performing both self-tests at home</b>	<b>2</b>
<b>Supplementary material 2: short questionnaire provided 10 days after test site visit</b>	<b>5</b>
<b>Supplementary material 3: Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures</b>	<b>6</b>
<b>Table S1 2x2 tables for primary and secondary analyses of the molecular reference test – saliva Ag-RDT comparison</b>	<b>8</b>
<b>Table S2 2x2 tables for primary and secondary analyses of the molecular reference test – nasal Ag-RDT comparison</b>	<b>9</b>
<b>Table S3 Follow-up information of participants that were tested again within 10 days after the initial test.</b>	<b>10</b>
<b>Figure S1 Sensitivities with 95% confidence intervals of the antigen rapid test-molecular reference standard test comparisons at viral load cut-off for infectiousness</b>	<b>11</b>
<b>Figure S2 Distribution of viral loads in participants with a positive molecular reference test, stratified by symptomatology at time of sampling.</b>	<b>12</b>

**Supplementary material 1: short questionnaire after performing both self-tests at home (translated from Dutch)**

1. What was the result of the saliva self-test?
  - Negative
  - Positive
  - I don't know: could not perform the test
  - I don't know: could not read the test result
  - Other, .....
  
2. What was the result of the nasal self-test?
  - Negative
  - Positive
  - I don't know: could not perform the test
  - I don't know: could not read the test result
  - Other, .....
  
3. What is the reason for testing?

*Multiple answers possible*

  - I have (had) Covid-19 like symptoms
  - I am a close contact of a SARS-CoV-2 infected person
    - Date of last contact: \_\_\_ - \_\_\_ (day – month)
  - I was notified because of:
    - The infected person is a household member  yes /  no
    - Received notification by CoronaMelder app (English: Corona notification app)  yes /  no
    - Received notification by public health service (by phone or letter)  yes /  no
    - Received notification by SARS-CoV-2 infected person  yes /  no
    - Other, .....
  - GP recommended a SARS-CoV-2 test
  - Travelled to a high-pandemic country
  - I performed a self-test and tested positive
    - What was the date of the positive self-test: \_\_\_ - \_\_\_ (day – month)
  - None of the above, but.....
  
4. Did you receive a Covid-19 vaccination?
  - No
  - Yes
    - If yes, which vaccine did you receive?  Pfizer  Moderna  AstraZeneca  Janssen  Unknown
    - How many vaccinations did you receive?  One  Two
    - What was the date of the last vaccination? \_\_\_ - \_\_\_ - \_\_\_ (day – month – year)
  
5. Did you have had a positive SARS-CoV-2 test previously? If yes, how long ago?
  - No
  - Yes
    - If yes, how long ago?  < 2 months  2-6 months  6-12 months  >12 months
  
6. At this moment, do you have any COVID-19 like symptoms?
  - No **GO TO QUESTION 9**
  - Yes
  
7. What COVID-19 like symptoms do you currently have?

*Multiple answers possible*

  - Common cold
  - Shortness of breath
  - Fever
  - Coughing
  - Loss of taste or smell
  - Muscle ache
  - I have other symptoms: .....

8. What was the moment you first experienced these symptoms?

- Today
- Yesterday
- Two days ago
- Three or more days ago

9. What is your highest level of education?

- Primary
- Secondary
- College / University, Bachelor's Degree
- College / University, Master's Degree

10. The saliva self-test instruction indicates you cannot eat, drink, smoke, brush your teeth or chew gum 30 minutes prior to the test, did you follow this instruction?

- Yes
- No

- If no, I

*Multiple answers possible*

- Ate
- drank
- 
- brushed
- my
- chewed gum
- smoked teeth

11. On a scale from 1 (very easy) to 5 (very hard), how difficult was it to perform the saliva self-test?

Very easy      1      2      3      4      5      very hard

12. On a scale from 1 (very easy) to 5 (very hard), how difficult was it to read the result off the saliva self-test?

Very easy      1      2      3      4      5      very hard

13. On a scale from 1 (very easy) to 5 (very hard), how difficult was it to perform the nasal self-test?

Very easy      1      2      3      4      5      very hard

14. On a scale from 1 (very easy) to 5 (very hard), how difficult was it to read the result off the nasal self-test?

Very easy      1      2      3      4      5      very hard

15. Do you agree with the following statements?

The instruction for use of the saliva self-test was clear

*Agree                      In doubt                      Disagree*

I am confident I performed the saliva self-test correctly

*Agree                      In doubt                      Disagree*

I would use this saliva self-test at home if I could

*Agree                      In doubt                      Disagree*

16. Do you prefer the saliva or nasal self-test?

- No
- Yes, I prefer the saliva self-test
- Yes, I prefer the nasal self-test

- If yes, why? .....

17. Do you have suggestions for improvement of the instruction for use of the saliva self-test or other suggestions?  
.....

**Supplementary material 2: short questionnaire provided 10 days after test site visit (translated from Dutch)**

1. Did you develop any Covid-19 like symptoms since your last corona test 10 days ago (see next question for list of possible symptoms)?  
 No  
 Yes
  
2. What COVID-19 like symptoms do you currently have?  
*Multiple answers possible*  
 Common cold  
 Shortness of breath  
 Fever  
 Coughing  
 Loss of taste or smell  
 Muscle ache  
 I have other symptoms: .....
  
3. What was the moment you first experienced these symptoms?  
 Today  
 Yesterday  
 Two days ago  
 Three or more days ago
  
4. Did you perform a corona test or was a corona test performed in the last 10 days since your corona test at the test site and the two self-tests performed for this study?  
 No ***THIS CONCLUDES THIS QUESTIONNAIRE***  
 Yes  
- If yes, what type of test was performed?  
 Test at a public health service test site  
 PCR  
 (Rapid) antigen test  
 I don't know  
 Test at a commercial test site  
 PCR  
 (Rapid) antigen test  
 I don't know  
 Self-test that I bought myself  
 Other, .....
  
5. What is the reason for testing?  
*Multiple answers possible*  
 I have (had) Covid-19 like symptoms  
 I am a close contact of a SARS-CoV-2 infected person  
- Date of last contact: \_\_\_ - \_\_\_ (day – month)  
I was notified because of:  
- The infected person is a household member  yes /  no  
- Received notification by CoronaMelder app (English: Corona notification app)  yes /  no  
- Received notification by public health service (by phone or letter)  yes /  no  
- Received notification by SARS-CoV-2 infected person  yes /  no  
- Other, .....
  
 GP recommended a SARS-CoV-2 test  
 Travelled to a high-pandemic country  
 I performed a self-test and tested positive  
- What was the date of the positive self-test: \_\_\_ - \_\_\_ (day – month)  
 None of the above, but.....  
6. What was the result of the corona test?  
 Positive (SARS-CoV-2 infection present)  
 Negative  
 No test result (test failed)

### Supplementary material 3: Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures

#### Specimen collection and SARS-CoV-2 diagnostic testing procedures

*West Brabant region, Microvida laboratories at Bravis hospital in Roosendaal; samples from Roosendaal*

One superficial combined oropharyngeal and nasal swab (about 2.5 cm deep from the edge of the nostril) was taken per person at the Public Health Service test sites at the test sites in Roosendaal, placed in universal transport media (HiViral™) with MagnaPure LC lysis- and binding buffer (Roche Diagnostics, The Netherlands), and transported to the Microvida laboratory in Roosendaal. RT-PCR was used as the reference standard test. RT-PCR was performed using the cobas SARS-CoV-2 test on the cobas 8800 platform (Roche Diagnostics International, Rotkreuz, Switzerland). Cycle threshold (Ct) values for the SARS-CoV-2 E-gene were converted to viral load (genome copies/ml) using an in-house established standard curve. The assay was used in accordance with the manufacturer's instructions; amplification curves and Ct values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive.

*Central- and Northeast Brabant region, Microvida laboratories at Elisabeth Twee Steden Ziekenhuis (ETZ) in Tilburg; samples from Tilburg*

One deep combined oropharyngeal-nasopharyngeal swab (>5 cm deep from the edge of the nostril) was taken per person at the Public Health Service test site in Tilburg, placed in 1x Tris-EDTA buffer (Sigma-Aldrich), and transported to the Microvida laboratory in Tilburg. One of two molecular tests were used as the reference test: the SARS-CoV-2 assay on the Alinity M molecular platform (Abbott) according to manufacturer's instructions, or an in-house RT-PCR as previously described using automated DNA extraction on a Qiagen Symphony with subsequent RT-PCR on a Qiagen Rotor-Gene platform.<sup>1</sup> RT-PCR positive samples were further analyzed on a cobas 8800 platform (in the Microvida laboratory in Roosendaal) to obtain Ct values for viral load calculation. Samples were stored at -80°C within 24 hours and thawed once for the cobas 8800 analysis.<sup>2</sup> In case of discrepant results (Alinity/in-house positive, cobas 8800 negative), a Ct value of 40 was assigned for subsequent analysis.

*Rotterdam city region, Erasmus Medical Center Viroscience laboratory: samples from south of Rotterdam (Zuidland)*

One deep combined OP-N swab (>5 cm deep from the edge of the nostril) swab was taken per person at the Public Health service test site in the Rotterdam-Rijnmond region (Zuidland), placed directly in universal transport media (HiViral™), and transported to the Erasmus MC Viroscience diagnostic laboratory. RT-PCR was used as the reference standard test. RT-PCR testing was performed in virus transport medium using the cobas SARS-CoV-2 test on the cobas 6800 platform. The assay was used in accordance with the manufacturer's instructions; amplification curves and cycle threshold values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive.

#### Viral load calculation

We used a viral load cut-off as a proxy of infectiousness of  $\geq 5.2 \log_{10}$  SARS-CoV-2 E-gene copies/mL, which was the viral load cut-off above which 95% of people with a positive molecular test had a positive virus culture in a recent previous study by our group.<sup>1</sup> For that study, the Erasmus MC Viroscience laboratory created a standard curve by testing dilutions of a specific quantified E-gene transcript (primary standard) available from the European Virus Archive (EVA<sup>g4</sup>) with the RT-PCR described by Corman et al.<sup>3</sup> The relation between Ct value and number of E-gene copies/ml was determined by linear regression analysis. Based on this calibration curve a secondary standard derived from cell-cultured virus was prepared and quantified. Serial dilutions of this secondary standard were tested by RT-PCR to prepare a secondary standard curve by linear regression.

In that previous study, we determined whether the cobas PCR platform at the Microvida laboratory provided comparable data to the cobas PCR platform at the Erasmus Medical Center Viroscience laboratory by having both laboratories test the same SARS-CoV-2 viral load panel obtained from the National Public Health Institute (RIVM). The Ct values generated in the two laboratories corresponded well. Therefore, we concluded that the same formula to convert Ct values into viral loads (copies/ml) could be used for the West-Brabant and Rotterdam laboratories. This formula was  $62.5 * e^{\frac{43.1-Ct}{1.607}}$ . The Microvida laboratory used different medium/reagent volumes per swab depending on the location. For each, a factor X was calculated based on the swab volume, dilution, and total sample volume, to allow alignment across samples with respect to the viral load in the Rotterdam standard. For example, if the sample volume is equal (3 ml in Tilburg compared to 3 ml in Rotterdam), but the dilution factor is higher, e.g., by the addition of lysis buffer (3 in Tilburg compared to 2 in Rotterdam), the effective viral sample would be lower than in the Rotterdam standard, thereby underestimating the actual viral load when using the above formula. To account for this, a factor  $X < 1$  was used, here 6/9. If dilution was lower, a factor  $X > 1$  was used. The conversion formula used therefore was  $62.5 * e^{\frac{43.1-Ct}{1.607}} / X$ .

## Self-tests

### Saliva Ag-RDT

The saliva Ag-RDT used in this study was the COVID-19 Antigen Rapid Test (Oral Fluid) for Self-testing by Hangzhou AllTest Biotech Co., Ltd., a CE-marked Ag-RDT. According to the instructions for use, participants had to cough deeply 3 to 5 times after which saliva could be spit in the test tube. After addition of buffer fluid, and squeezing the test tube 10-15 times, two droplets of the solvent could be added to the testing cassette. After 15 minutes, but no later than 20 minutes, the participant could read the test result visually from the testing cassette.

### Nasal Ag-RDT

The nasal Ag-RDT used in this study was the SD Biosensor SARS-CoV-2 Rapid Antigen Self-Test Nasal, distributed by Roche Diagnostics, a CE-marked Ag-RDT. According to the instructions for use, a sample should be taken by placing a nasal swab 2 cm deep in the nose and twisting it 4 times for 15 seconds, once in each nostril. Afterwards the nose swab had to be placed in a test tube that was filled by buffer fluid and twisted 10 times during which the test tube had to be squeezed lightly. While squeezing the tube, the swab could be removed from the tube, while leaving all the test fluid in the tube. Then, 4 droplets of the solvent had to be added to the testing cassette. After 15 minutes, but no later than 30 minutes, the participant had to read the test result visually from the testing cassette.

### Analytical performance

The analytical performances of the Hangzhou AllTest Biotech and the SD Biosensor lateral flow test devices were assessed using a national External Validation Quality Assessment panel (LEQA) for SARS-CoV-2 Ag-RDTs. The LEQA Ag panel contained four different SARS-CoV-2 strains, including:

hCoV-19/Netherlands/NoordBrabant\_10003/2020 (B.11, 19A);

hCoV-19/Netherlands/GE-RIVM-20300/2020 (B.1.177, 20AEU1);

hCoV-19/Netherlands/NH-RIVM-20432/2020 (B.1.1.7, 20B/501Y.V1); and

hCoV-19/Netherlands/NB-RIVM-20274/2020 (B.1.5, 20A).

These strains had been deactivated by 2-hour incubation with Triton X-100 at room temperature.

The results of the panel assessment are presented in the Table below and show that both devices had good analytical performance. Furthermore, the analytical performance of the two devices were very similar.

LEQA Ag panel	SARS-CoV-2 strain	Concentration TCID50/ml	Hangzhou AllTest Biotech	SD Biosensor
LEQAA1_Ag21-01	B.1.177 20A.EU1	1334	++	++
LEQAA1_Ag21-02	B.11; 19A; wildtype	7499	++	++
LEQAA1_Ag21-03	B.1.1.7 20B/501Y.V1	23714	++	++
LEQAA1_Ag21-04	B.11; 19A; wildtype	75	+	(+)
LEQAA1_Ag21-05	B.1.1.7 20B/501Y.V1	237	+	+
LEQAA1_Ag21-06	B.1.177 20A.EU1	13335	++	++
LEQAA1_Ag21-07	B.1.5 20A	2371	++	++
LEQAA1_Ag21-08	B.1.177 20A.EU1	133	++	+
LEQAA1_Ag21-09	Negative		-	-
LEQAA1_Ag21-10	B.1.1.7 20B/501Y.V1	2371	++	++
LEQAA1_Ag21-11	B.11; 19A; wildtype	7	(+)	-
LEQAA1_Ag21-12	B.1.5 20A	23714	++	++
LEQAA1_Ag21-13	B.11; 19A; wildtype	750	++	+
LEQAA1_Ag21-14	B.1.5 20A	237	++	+
LEQAA1_Ag21-15	B.11; 19A; wildtype	74989	++	++

TCID50 = Median Tissue Culture Infectious Dose

- = negative; (+) = faint positive; + = positive; ++ = strong positive

## References

1. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, et al. Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During an Early Phase of the Pandemic. *JAMA Netw Open* 2020; **3**(5): e209673.
2. Stohr J, Wennekes M, van der Ent M, et al. Clinical performance and sample freeze-thaw stability of the cobas(R)6800 SARS-CoV-2 assay for the detection of SARS-CoV-2 in oro-/nasopharyngeal swabs and lower respiratory specimens. *J Clin Virol* 2020; **133**: 104686.

**Table S1 2x2 tables for primary and secondary analyses of the molecular reference test – saliva Ag-RDT comparison**

Analysis	Subgroup	Ref+	Ref-	Total		
<b>Primary</b>		<b>Test+</b>	<b>85</b>	<b>26</b>	<b>111</b>	
		<b>Test-</b>	<b>97</b>	<b>2595</b>	<b>2692</b>	
		<b>Total</b>	<b>182</b>	<b>2621</b>	<b>2803</b>	
<b>Secondary (stratified):</b>						
Infectiousness viral load cut-off¶		Ref+	Ref-	Total		
		Test+	78	32	110	
		Test-	64	2614	2678	
		Total	142	2646	2788	
Symptoms present at sampling‡:	Yes		Ref+	Ref-	Total	
			Test+	77	25	102
			Test-	74	2130	2204
		Total	151	2155	2306	
	No		Ref+	Ref-	Total	
			Test+	8	1	9
		Test-	23	452	475	
	Total	31	453	484		
Vaccinated (at least 1 one)®:	Yes		Ref+	Ref-	Total	
			Test+	54	22	76
			Test-	61	2253	2314
		Total	115	2275	2390	
	No		Ref+	Ref-	Total	
			Test+	31	4	35
		Test-	36	333	369	
	Total	67	337	404		
Previous SARS-CoV-2 infection§:	Yes		Ref+	Ref-	Total	
			Test+	4	3	7
			Test-	16	343	359
		Total	20	346	366	
	No		Ref+	Ref-	Total	
			Test+	81	23	104
		Test-	81	2242	2323	
	Total	162	2265	2427		
Sex†:	Female		Ref+	Ref-	Total	
			Test+	41	13	54
			Test-	67	1590	1657
		Total	108	1603	1711	
	Male		Ref+	Ref-	Total	
			Test+	44	13	57
		Test-	29	995	1024	
	Total	73	1008	1081		
Age [years] #:	≥16 to ≤40		Ref+	Ref-	Total	
			Test+	38	15	53
			Test-	54	1343	1397
		Total	92	1358	1450	
	>40 to ≤65		Ref+	Ref-	Total	
			Test+	36	9	45
			Test-	36	1054	1090
		Total	72	1063	1135	
	>65		Ref+	Ref-	Total	
		Test+	11	2	13	
		Test-	6	189	195	
	Total	17	191	208		

¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>6</sup>, was 5.2 log<sub>10</sub> SARS-CoV-2 E-gene copies/mL. Viral load unavailable for 19 individuals.

‡Symptoms not available for 13 participants.

® COVID-19 vaccination status not available for 9 participants.

§ Previous SARS-CoV-2 infection information not available for 10 participants.

† Sex not available for 11 participants.

# Age not available for 10 participants.



**Table S2 2x2 tables for primary and secondary analyses of the molecular reference test – nasal Ag-RDT comparison**

Analysis	Subgroup	Ref+	Ref-	Total		
<b>Primary</b>		<b>Test+</b>	<b>124</b>	<b>12</b>	<b>136</b>	
		<b>Test-</b>	<b>56</b>	<b>2627</b>	<b>2683</b>	
		<b>Total</b>	<b>180</b>	<b>2639</b>	<b>2819</b>	
<b>Secondary (stratified):</b>	Infectiousness viral load cut-off¶		Ref+	Ref-	Total	
		Test+	120	13	133	
		Test-	23	2648	2671	
		Total	143	2661	2804	
	Symptoms present at sampling‡:	Yes		Ref+	Ref-	Total
			Test+	117	10	127
			Test-	32	2160	2192
		Total	149	2170	2319	
		No		Ref+	Ref-	Total
			Test+	7	2	9
	Test-		24	454	478	
	Total	31	456	487		
	Vaccinated (at least 1 one)®:	Yes		Ref+	Ref-	Total
			Test+	75	10	85
			Test-	32	2272	2304
		Total	107	2282	2389	
		No		Ref+	Ref-	Total
			Test+	49	2	51
	Test-		24	346	370	
	Total	73	348	421		
	Previous SARS-CoV-2 infection§:	Yes		Ref+	Ref-	Total
			Test+	7	3	10
			Test-	12	350	362
		Total	19	353	372	
No			Ref+	Ref-	Total	
		Test+	117	9	126	
	Test-	44	2267	2311		
Total	161	2276	2437			
Sex†:	Female		Ref+	Ref-	Total	
		Test+	73	7	80	
		Test-	33	1604	1637	
	Total	106	1611	1717		
	Male		Ref+	Ref-	Total	
		Test+	51	5	56	
Test-		22	1012	1034		
Total	73	1017	1090			
Age [years]#:	≥16 to ≤40		Ref+	Ref-	Total	
		Test+	62	7	69	
		Test-	31	1363	1394	
		Total	93	1370	1463	
	>40 to ≤65		Ref+	Ref-	Total	
		Test+	51	4	55	
		Test-	19	1065	1084	
		Total	70	1069	1139	
	>65		Ref+	Ref-	Total	
		Test+	11	1	12	
		Test-	5	189	194	
		Total	16	190	206	

¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>6</sup>, was 5.2 log<sub>10</sub> SARS-CoV-2 E-gene copies/mL. Viral load unavailable for 19 individuals.

‡Symptoms not available for 13 participants.

® COVID-19 vaccination status not available for 9 participants.

§ Previous SARS-CoV-2 infection information not available for 10 participants.


† Sex not available for 12 participants.

# Age not available for 11 participants.

**Table S3 Follow-up information of participants that were tested again within 10 days after the initial test.** Information was not available for 794 (28.3%) and 796 (28.2%) of participants with saliva and nasal Ag-RDT result available, respectively. Of the remaining participants 1758 (87.5%) and 1772 (87.6%) were not tested within 10 days after the initial test.

Test result available from the reference test and...	Saliva Ag-RDT	Nasal Ag-RDT
Sample size (Test during 10-day follow-up)	N = 251/2009 (12.5%)	N = 251/2029 (12.4%)
Testing information, n (%) <sup>1</sup>		
Symptomatic	74 (29.5)	74 (29.5)
Asymptomatic – close contact of confirmed SARS-CoV-2 infected household member	0 (0.0)	0 (0.0)
Asymptomatic – close contact of other confirmed SARS-CoV-2 infected individual	40 (15.9)	41 (16.3)
Asymptomatic – other	137 (54.6)	136 (54.2)
Type of test, n (%)		
public health service COVID-19 test sites		
RT-PCR test	71 (28.3)	70 (27.9)
Ag-RDT	44 (62.0)	44 (62.9)
Unknown	2 (2.8)	2 (2.9)
Commercial test site		
RT-PCR test	25 (35.2)	24 (34.2)
Ag-RDT	24 (9.6)	24 (9.6)
Unknown	5 (20.8)	5 (20.8)
Self-test	16 (66.7)	16 (66.7)
Other (e.g., via work, school)	3 (12.5)	3 (12.5)
Test result		
Positive	126 (50.2)	127 (50.6)
Negative	30 (12.0)	30 (12.0)
Unknown	8 (3.2)	8 (3.2)
	240 (95.6)	240 (95.6)
	3 (1.2)	3 (1.2)

**Figure S1** Sensitivities with 95% confidence intervals of the antigen rapid test-molecular reference standard test comparisons at viral load cut-off for infectiousness (i.e., viral load  $<5.2 \log_{10}$  SARS-CoV-2 E-gene copies/mL is considered as a negative reference test result), stratified according to symptomatology, COVID-19 vaccination status, previous infection status, sex, and age. The vertical line indicates the sensitivity of the Ag-RDT in the overall study population before application of a viral load cut-off (see Figure 2), and the number of positive molecular tests out of the total or subgroup between parentheses.



**Figure S2** Distribution of viral loads in participants with a positive molecular reference test, stratified by symptomatology at time of sampling.

